The Novel Nutraceutical KJS018A Prevents Hepatocarcinogenesis Promoted by Inflammation

Figure 4

KJS018A suppresses hepatic tumor development via downregulation of Cox-2 and IL-6. (a) Body weights of mice with and without KJS018A treatment (5 mg/kg). (b) Tumor sections (left) and weights (right) with and without KJS018A treatment (5 mg/kg). (c) Tumor sizes of SNU398 and HepG2 with and without KJS018A treatment (5 mg/kg). (d) Immunofluorescence staining of Cox-2 and IL-6 expression in hepatic tumors with and without KJS018A treatment (5 mg/kg). Scale bar, 20 μm. P< 0.01; P< 0.001; P< 0.0001.

(a)

(b)

(c)

(d)